论文部分内容阅读
目的探讨紫杉醇同步放化疗在晚期子宫内膜癌的临床治疗中的应用。方法选取2013年5月—2014年10月晚期子宫内膜癌患者180例,随机数字法分为观察组和对照组各90例。对照组给予放射治疗,观察组给予紫杉醇同步放化疗治疗。对两组临床疗效、不良反应、3年内肿瘤远处转移和局部复发情况及5年生存情况进行观察。结果观察组治疗总有效率为81.44%,明显高于对照组的51.55%,差异有统计学意义(P<0.05);观察组骨髓抑制发生率和胃肠道反应发生率分别为32.22%、34.44%,均显著高于对照组的11.11%、12.22%,差异均有统计学意义(均P<0.05);观察组3年内肿瘤远处转移率和局部复发率分别为10.00%、8.89%,均明显低于对照组的28.89%、27.78%,差异均有统计学意义(均P<0.05);观察组5年生存率为88.89%,显著高于对照组的67.78%,差异均有统计学意义(P<0.05)。结论紫杉醇同步放化疗治疗晚期子宫内膜癌疗效显著,可延长患者的生存期,值得推广与使用。
Objective To investigate the application of paclitaxel concurrent chemoradiotherapy in the treatment of advanced endometrial cancer. Methods 180 patients with endometrial cancer from May 2013 to October 2014 were selected and randomly divided into observation group and control group with 90 cases in each group. The control group was given radiotherapy and the observation group was treated with paclitaxel concurrent chemoradiotherapy. Two groups of clinical efficacy, adverse reactions, 3 years distant metastasis and local recurrence of tumor and 5-year survival were observed. Results The total effective rate in observation group was 81.44%, which was significantly higher than that in control group (51.55%), the difference was statistically significant (P <0.05). The incidence of bone marrow suppression and gastrointestinal reaction in observation group were 32.22% and 34.44 %, Both of which were significantly higher than that of the control group (11.11%, 12.22%, both P <0.05). The rates of distant metastasis and local recurrence in the observation group were 10.00% and 8.89% (P <0.05). The 5-year survival rate of the observation group was 88.89%, which was significantly higher than that of the control group (67.78%), the differences were statistically significant (P <0.05). Conclusion Paclitaxel concurrent chemoradiotherapy for advanced endometrial cancer has significant curative effect, prolonging the survival of patients and deserving promotion and use.